Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy 
in Elderly Patients with Advanced NSCLC

The incidence of cancer is closely correlated with age, as 75% of non-small cell lung cancer (NSCLC) patients are aged at least 65 years. The availability of immune checkpoint inhibitors (ICIs) has altered the available NSCLC therapeutic pattern. Limited studies on elderly patients have demonstrated...

Full description

Bibliographic Details

Published in:	Chinese Journal of Lung Cancer
Main Authors:	Yunye MAO, Shu SHENG, An WANG, Jinzhao ZHAI, Xiangwei GE, Di LU, Jinliang WANG
Format:	Article
Language:	Chinese
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-05-01
Subjects:	lung neoplasms elderly non-small cell lung cancer immunosenescence immunotherapy immunotherapy combined with low-intensity chemotherapy
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.10